Organogenesis Holdings Inc. (ORGO) AI Stock Analysis

Organogenesis Holdings Inc. operates in the regenerative medicine market, developing, manufacturing, and commercializing solutions for advanced wound care, surgical, and sports medicine across the United States. Its advanced wound care line includes Affinity, Apligraf, and Dermagraft, which utilize living cells, human collagen, and extracellular matrix proteins to facilitate wound healing. In surgical and sports medicine, products such as NuCel and ReNu support native tissue healing, while FiberOS and OCMP act as bone void fillers. The company also advances pipeline solutions like PuraPly XT, PuraPly MZ, PuraForce, and TransCyte, serving healthcare providers including hospitals and wound care centers.

Between FY2021 and FY2025, Organogenesis increased annual revenue from $467.4M to $563.0M, achieving a 5-year revenue CAGR of 10.7%. Net income rose to $37.0M in FY2025 with a net margin of 6.6%, rebounding from $861,000 in FY2024. Gross margins remained stable across this span, finishing at 75.6% in FY2025. However, trailing twelve month revenue stands at $457.5M with an operating margin of -119.3% and a profit margin of -18.4%. In the latest quarter ending June 30, 2026, quarterly revenue fell 56.7% year-over-year, while quarterly earnings growth reached 555.2%.

As of June 30, 2026, Organogenesis held $46.1M in cash and short-term investments against total debt of $67.0M, resulting in net debt of $20.9M. The company maintains a current ratio of 3.52 and a debt-to-equity ratio of 0.23, backed by $288.1M in shareholders' equity and $406.4M in total assets. During FY2025, operating cash flow was -$10.3M and free cash flow was -$24.5M, alongside capital expenditures of $14.2M.

ORGO closed at $1.00 on October 16, 2026, representing an 80.7% decline year-to-date and a 75.4% drop over the trailing twelve months, trailing the S&P 500 return of 16.8%. The company has a market cap of $128.6M and an enterprise value of $347.3M. Its forward P/E ratio of 12.7x and EV/EBITDA of 10.7x sit below the median of its US-listed Healthcare peers, which stand at 17.3x and 12.0x, respectively. Organogenesis also trades at a price-to-sales ratio of 0.3x, compared to 4.1x for its peer median.

Wall Street coverage tracked on Organogenesis includes 2 Hold ratings, with zero Buy or Sell recommendations. The mean price target is $2.00, representing a 100.0% premium over the last close of $1.00. For the current fiscal year ending December 31, 2026, analysts estimate an EPS of -$1.38 and revenue of $196.1M. Over the last four quarters, the company beat EPS estimates 2 times. The next earnings date is scheduled for November 5, 2026.

This page is an AI-written research summary of Organogenesis Holdings Inc. (ORGO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ORGO income statement, ORGO balance sheet, ORGO key metrics, ORGO analyst forecast, ORGO chart. See the ORGO stock overview for the latest quote and news.